Fierce Pharma Engage 2025

Gain insights into the complexities of valuing platform technologies, exploring methodologies to capture their full potential and manage uncertainties in deal-making.

• Examine innovative approaches to assess the scalability and long-term value of platform technologies.
• Explore strategies to align valuation expectations between partners in platform-focused collaborations.
• Learn from case studies highlighting successful valuation frameworks for platform deals in emerging modalities.

AI is reshaping the pharmaceutical landscape, but how can BD&L professionals move from hype to practical value? This session will explore real-world applications of data- and AI-driven insights in BD&L strategy, focusing on key challenges such as assessing deal quality, predicting asset success, optimizing portfolio decisions, and evaluating the competitive landscape. Attendees will further their knowledge on identifying early-stage, high-potential investments more confidently with the right combination of data, AI, and solution partner.

In this case study-driven presentation, hear how one founder turned a platform concept into a credible partner for big pharma—before a single asset was in the clinic. From leading multi-million dollar AI-based discovery deals at Absci to building a new venture at Lily Gateway Labs, this talk offers practical insights into what it takes to successfully market, scale, and exit a platform company in today’s competitive environment.

• Learn how to position an early-stage platform to secure partnerships with big pharma—even without clinical assets.
• Hear lessons from high-profile partnerships with Merck, EQRx, AZ, and Almirall, including what worked (and what didn’t).
• Explore how platform companies can build credibility, define value, and navigate partnership dynamics from startup to acquisition.